Lawrence Michael Kauvar
Principal investigator.
Biotech
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2015First federal award
$14.6MFederal grants as PI14 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
14 awards · $14.6M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Aug 19, 2022 | NIH | SBIR Phase II Biofilm disrupting antibody to treat respiratory and musculoskeletal infections | $989K | TRELLIS BIOSCIENCE, INC. |
| Jan 15, 2022 | NIH | SBIR Phase II Strain-Independent Therapeutic Antibodies for Influenza | $1000K | TRELLIS BIOSCIENCE, INC. |
| Aug 2, 2021 | NIH | SBIR Phase II Biofilm disrupting antibody to treat respiratory and musculoskeletal infections | $991K | TRELLIS BIOSCIENCE, INC. |
| Feb 1, 2021 | NIH | SBIR Phase II Strain-Independent Therapeutic Antibodies for Influenza | $999K | TRELLIS BIOSCIENCE, INC. |
| Dec 23, 2020 | NIH | SBIR Phase II Therapeutic Antibody for RSV IIB | $998K | TRELLIS BIOSCIENCE, INC. |
| Sep 1, 2020 | NIH | SBIR Phase II Biofilm disrupting antibody to treat respiratory and musculoskeletal infections | $999K | TRELLIS BIOSCIENCE, INC. |
| Nov 29, 2019 | NIH | SBIR Phase II Therapeutic Antibody for RSV IIB | $1.0M | TRELLIS BIOSCIENCE, INC. |
| Dec 11, 2018 | NIH | SBIR Phase II Therapeutic Antibody for RSV IIB | $1.0M | TRELLIS BIOSCIENCE, INC. |
| Jun 14, 2017 | NIH | SBIR Phase II Strain-Independent Therapeutic Antibodies for Influenza | $981K | TRELLIS BIOSCIENCE, INC. |
| Jan 10, 2017 | NIH | SBIR Phase II Therapeutic antibody for RSV | $1.5M | TRELLIS BIOSCIENCE, INC. |
| Jun 8, 2016 | NIH | SBIR Phase II Strain-Independent Therapeutic Antibodies for Influenza | $987K | TRELLIS BIOSCIENCE, INC. |
| Jan 31, 2016 | NIH | SBIR Phase II Therapeutic antibody for RSV | $1.3M | TRELLIS BIOSCIENCE, INC. |
| Jun 17, 2015 | NIH | SBIR Phase II Strain-Independent Therapeutic Antibodies for Influenza | $942K | TRELLIS BIOSCIENCE, INC. |
| Jan 15, 2015 | NIH | SBIR Phase II Therapeutic Antibodies for CMV | $991K | TRELLIS BIOSCIENCE, INC. |
Peer ranks
Federal funding#18
Awards as PI#57
Patents#273
Companies
- TRELLIS BIOSCIENCE, INC.Linked by awards · Biotech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.